Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Int J Mol Sci ; 20(13)2019 Jul 05.
Article in English | MEDLINE | ID: mdl-31284427

ABSTRACT

This study investigated the effect of a novel progestin and its combination with metformin on the growth of endometrial cancer (EC) cells. Inhibitory effects of four progestins, including nomegestrol acetate (NOMAC), medroxyprogesterone acetate, levonorgestrel, and cyproterone acetate, were evaluated in RL95-2, HEC-1A, and KLE cells using cell counting kit-8 assay. Flow cytometry was performed to detect cell cycle and apoptosis. The activity of Akt (protein kinase B), mTOR (mammalian target of rapamycin) and its downstream substrates 4EBP1 (4E-binding protein 1) and eIF4G (Eukaryotic translation initiation factor 4G) were assayed by Western blotting. Nude mice were used to assess antitumor effects in vivo. NOMAC inhibited the growth of RL95-2 and HEC-1A cells, accompanied by arresting the cell cycle at G0/G1 phase, inducing apoptosis, and markedly down-regulating the level of phosphorylated mTOR/4EBP1/eIF4G in both cell lines (p < 0.05). Metformin significantly increased the inhibitory effect of and apoptosis induced by NOMAC and strengthened the depressive effect of NOMAC on activity of mTOR and its downstream substrates, compared to their treatment alone (p < 0.05). In xenograft tumor tissues, metformin (100 mg/kg) enhanced the suppressive effect of NOMAC (100 mg/kg) on mTOR signaling and increased the average concentration of NOMAC by nearly 1.6 times compared to NOMAC treatment alone. Taken together, NOMAC suppressing the growth of EC cells likely correlates to down-regulating the activity of the mTOR pathway and metformin could strengthen this effect. Our findings open a new window for the selection of progestins in hormone therapy of EC.


Subject(s)
Down-Regulation/drug effects , Endometrial Neoplasms/enzymology , Endometrial Neoplasms/pathology , Megestrol/pharmacology , Metformin/pharmacology , Norpregnadienes/pharmacology , TOR Serine-Threonine Kinases/metabolism , Adaptor Proteins, Signal Transducing , Animals , Apoptosis/drug effects , Cell Cycle Checkpoints/drug effects , Cell Cycle Proteins , Cell Line, Tumor , Cell Proliferation/drug effects , Estrogen Receptor alpha/metabolism , Eukaryotic Initiation Factor-4G/metabolism , Female , Humans , Megestrol/chemistry , Metformin/chemistry , Mice, Nude , Norpregnadienes/chemistry , Phosphorylation/drug effects , Receptors, Progesterone/metabolism , Tumor Suppressor Protein p53/metabolism , Xenograft Model Antitumor Assays
2.
Yao Xue Xue Bao ; 46(10): 1262-7, 2011 Oct.
Article in Chinese | MEDLINE | ID: mdl-22242462

ABSTRACT

Double cannulation model of conscious rat allowing simultaneous collection of mesenteric lymph and jugular venous blood was established to investigate the intestinal lymphatic transport of breviscapine orally administered in rat. The concentrations of breviscapine in plasma and lymph were determined by HPLC. The pharmacokinetics of breviscapine after oral and intravenous administration was evaluated in the conscious rat model. It was observed that scutellarin distributed from blood circulation to lymphatic system after intravenous injection. The cumulative lymphatic transport amount within 12 h was (2.78 +/- 0.25) microg, equivalent to 0.0792% of intravenous dose. After oral administration of scutellarin to double-cannulation rats, the cumulative lymphatic transport amount within 12 h was (0.92 +/- 0.08) microg, equal to 0.0083% of oral dose. The absolute bioavailability of breviscapine orally administered to double-cannulation rats was 4.91%, indicating that scutellarin was mainly absorbed into the bloodstream through the portal vein. Lymphatic transport of scutellarin appears to reflect high affinity for the lymph lipoproteins to chylomicron. This study provided a biopharmaceutics basis for developing oral lipid delivery system for the promotion of intestinal lymphatic transport to improve oral bioavailability of breviscapine.


Subject(s)
Apigenin/metabolism , Flavonoids/pharmacokinetics , Glucuronates/metabolism , Intestinal Absorption , Lymphatic System/metabolism , Administration, Oral , Animals , Apigenin/blood , Area Under Curve , Biological Availability , Biological Transport , Drug Delivery Systems/methods , Flavonoids/administration & dosage , Flavonoids/isolation & purification , Glucuronates/blood , Injections, Intravenous , Male , Plants, Medicinal/chemistry , Portal Vein/metabolism , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...